Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975294 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| SCHEMBL1101673 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| SCHEMBL3799193 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| SCHEMBL374714 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| SCHEMBL375078 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| SCHEMBL12463720 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| SCHEMBL3690265 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| Hydrochloric Acid SCHEMBL9985470 | 0.98 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| Hydrochloric Acid SCHEMBL374713 | 0.98 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 | |
| Hydrochloric Acid SCHEMBL6117198 | 0.98 | ALDH1A1 (0.35) | ALDH1A1NPSR1ATMGAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| EP-2283018-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6767991-B1 | PEPTIDES AND ANALOGS THEREOF; VIRAL PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH PEPTIDES AND RIBAVIRIN | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-27 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| US-6410531-B1 | FOR THERAPY OF HEPATITIS C VIRUS (HCV) INFECTION | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-06-25 | — | — | US | disclosed |
| US-6329379-B1 | OLIGOPEPTIDES FOR INHIBITING HEPATITIS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6323180-B1 | PROTEASE INHIBITORS; INHIBIT REPLICATION OF HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2001-11-27 | — | — | US | disclosed |
| US-6268207-B1 | RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-07-31 | — | — | US | disclosed |
| EP-1105413-A2 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009543-A2 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885NPSR1 1576/4885ATM 4045/4885 |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | ALDH1A1 576/4885NPSR1 4081/4885ATM 4225/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885NPSR1 1576/4885ATM 4045/4885 |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | ALDH1A1 4292/4885NPSR1 1006/4885ATM 3874/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | ALDH1A1 4253/4885NPSR1 2504/4885ATM 4132/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | ALDH1A1 719/4885NPSR1 3225/4885ATM 3744/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | ALDH1A1 4292/4885NPSR1 1006/4885ATM 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.